Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT02302690 Completed - Clinical trials for Crigler Najjar Syndrome

Immunity Against AAV in Crigler Najjar Patient

Start date: November 2014
Phase: N/A
Study type: Observational

The proposed research protocol aims at addressing these points by pre-screening CN patients for their AAV serology in link with their medical history and current medical status. A first objective is to assess the presence of neutralizing AAV antibodies in the serum of CN patients.

NCT ID: NCT02302326 Completed - Clinical trials for Polycystic Ovary Syndrome

Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome

PI12/1984
Start date: January 2013
Phase: N/A
Study type: Interventional

The main objective of the present project is to evaluate the relevance of reticulum stress in the pathogenesis of polycystic ovary syndrome (PCOS), focusing particularly on the underlying mechanisms of insulin resistance, which is the origin of metabolic comorbidities. Furthermore, the investigators will assess the potential of insulin sensitizers as a treatment to control endoplasmic reticulum stress markers in PCOS patients.

NCT ID: NCT02302274 Completed - Brugada Syndrome Clinical Trials

Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

Start date: July 1, 2010
Phase:
Study type: Observational

The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.

NCT ID: NCT02300558 Terminated - Clinical trials for Long QT Syndrome Type 3

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Start date: December 17, 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension (OLE) phase.

NCT ID: NCT02299973 Completed - Clinical trials for Irritable Bowel Syndrome

Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating

Start date: October 2014
Phase: N/A
Study type: Interventional

Intestinal microbiota dysbiosis is thought to play an important role in the complex pathophysiology of irritable bowel syndrome (IBS), especially in diarrhoea-predominant IBS and possibly in IBS with severe bloating. Fecal microbiota transplantation or FMT has been shown to be an effective means of correcting this imbalance in the gut microbiota, especially in patients with recurrent Clostridium difficile infections where it has become a preferred treatment strategy. In a preliminary pilot study in 12 patients we found that FMT was a safe and accepted therapy in IBS patients. In 75% of patients an amelioration of IBS symptoms in general and abdominal bloating was seen three months after transplantation. In this study the effects of FMT on patients with IBS without constipation and bloating will be investigated in a double blind, placebo controlled RCT.

NCT ID: NCT02298621 Completed - Metabolic Syndrome Clinical Trials

Pomegranate Juice and Metabolic Syndrome

Start date: January 2013
Phase: N/A
Study type: Interventional

The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome.

NCT ID: NCT02298335 Completed - Clinical trials for Nephrotic Syndrome,Idiopathic

Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome:a Prospective Observational Study

Start date: May 13, 2014
Phase: N/A
Study type: Interventional

This study is to assess the efficacy and safety of 8-weeks full-dose induction protocol (prednisone 1mg/kg, maximum 60mg/day) and protracted tapering protocol in the treatment of adult idiopathic nephrotic syndrome.

NCT ID: NCT02297945 Completed - Cushing's Syndrome Clinical Trials

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

PROMPT
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.

NCT ID: NCT02297555 Terminated - Metabolic Syndrome Clinical Trials

ENDOBARRIER® and Conventional Therapy in the Management of Metabolic Syndrome in Obese Patients

ENDOMETAB
Start date: April 2014
Phase: N/A
Study type: Interventional

Obesity and metabolic syndrome (MS) are closely interrelated leading to increased mortality, mainly due to cardiovascular disease. In addition, some cancers are much higher when obesity is associated with metabolic syndrome. Bariatric surgery allows significant and sustained weight loss with marked improvement of MS. Considered too invasive, surgery is proposed to a small proportion of patients who could theoretically benefit. The ENDOBARRIER® device implanted endoscopically is an innovative approach developed for management of obesity in the non-surgical manner with benefits for improvement in MS already reported in literature.

NCT ID: NCT02297451 Completed - Clinical trials for Renal Failure, End-Stage

Trial Comparing the Incidence of Steal Syndrome in the Two Types of anTEcubitaL Fossa Arteriovenous fistuLa AVF

STEAL
Start date: February 2011
Phase: N/A
Study type: Interventional

Background: Arteriovenous fistula (AVF) is a form of vascular access for haemodialysis. An AVF is normally created at the level of the wrist, but occasionally it is created in the elbow when there is no suitable vessel in the forearm. The most common type of elbow (antecubital) fistula (AFF) is a brachiocephalic fistula, which carries significantly higher risk of steal syndrome (AVF-associated hand ischaemia) than wrist fistulas. More recently, AFF using proximal radial or ulnar artery as inflow has been described and shown to have a lower rate of Steal syndrome than brachiocephalic fistula. This study aims to investigate the incidence of steal syndrome between AFF using brachial artery and that using the proximal radial/ulnar artery as inflow.